2026-04-14T17:45:31Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/58102025-02-26T10:17:21Zcom_10324_1179com_10324_931com_10324_894col_10324_1306

Pérez Castrillon, José Luis Silva, Jesús Justo, Isabel Sanz Cantalapiedra, Alberto Martín-Luquero Ibáñez, Miguel Igea, Rosa Escudero, Pilar Pueyo, Carol Díaz, Cristina Hernández, Gonzalo Dueñas Laita, Antonio 2014-09-03T11:35:06Z 2015-09-03T23:40:10Z 2003 American Journal of Hypertension, 2003, vol. 16, p. 453-459 0895-7061 http://uvadoc.uva.es/handle/10324/5810 10.1016/S0895-7061(03)00845-8 453 459 American Journal of Hypertension 16 Background: Many alterations in extracellular metabolism of calcium have been associated to hypertension, but the number of studies relating this disease with osteoporosis is extremely low. This study clarifies the therapeutic effect of three treatments— quinapril, quinapril hydrochlorothiazide (HCTZ), enalapril—on bone remodeling markers, bone mineral density (BMD) in hypertensive patients, and relationship with angiotensin converting enzyme (ACE) polymorphism. eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 International Hipertension arterial - Tratamiento Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms info:eu-repo/semantics/article